US 12,247,257 B2
Blood biomarkers of stroke
Serge Timsit, Brest (FR); and Emmanuelle Genin, Plougastel-Daoulas (FR)
Assigned to CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE BREST, Brest Cedex (FR); ÉTABLISSSEMENT FRANÇAIS DU SANG, Saint-Denis (FR); INSERM (INSTITUT NATIONAL DE LA SANTÉET DE LA RECHERCHE MÉDICALE), Paris Cedex 13 (FR); and UNIVERSITÉ DE BRETAGNE OCCIDENTALE, Brest (FR)
Appl. No. 17/054,820
Filed by CENTRE HOSPITALIER RÉGIONAL ET UNIVERSITAIRE DE BREST, Brest (FR); ÉTABLISSEMENT FRANÇAIS DU SANG, Saint-Denis (FR); INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); and UNIVERSITÉ DE BRETAGNE OCCIDENTALE, Brest (FR)
PCT Filed May 16, 2019, PCT No. PCT/EP2019/062653
§ 371(c)(1), (2) Date Nov. 12, 2020,
PCT Pub. No. WO2019/219831, PCT Pub. Date Nov. 21, 2019.
Claims priority of application No. 18305600 (EP), filed on May 16, 2018.
Prior Publication US 2021/0214793 A1, Jul. 15, 2021
Int. Cl. G01N 33/53 (2006.01); C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01)] 6 Claims
 
1. A method for eliminating or reducing the symptoms of a stroke, for slowing or eliminating the progression of a stroke, and/or for delaying the initial occurrence or the reoccurrence of a stroke, in a human or a non-human primate subject identified as being affected by stroke or as being at risk of having a stroke, comprising:
a. identifying the subject as being affected with a stroke or as being at risk of having a stroke by:
i) determining a signature in a sample obtained from the subject by measuring the expression levels of at least three biomarkers selected from the group consisting of PTGS2, HMOX1, LDLR, HSPA1B, G0S2, BAG3, TM4SF1, DUSP1 and ADM wherein the sample is a blood sample, a plasma sample, a serum sample, or a saliva sample;
ii) comparing the signature determined in step i) with a reference signature;
iii) identifying the subject with the expression levels of the at least three biomarkers in the signature are higher than the expression levels of the same at least three biomarkers in the reference signature as being affected with a stroke or as being at risk of having a stroke; and
b. administering thrombectomy, antithrombotic agents, anticoagulants, antiplatelet drugs, thrombolytic drugs, a neuroprotective agent, hypothermia, or a combination thereof, to treating or preventing the stroke in the subject identified as being affected with a stroke or as being at risk of having a stroke.